BioMarin To Get Royalties From Ascendis Under IP Settlement
BioMarin and Ascendis Pharma settled a patent dispute, with Ascendis agreeing to pay BioMarin royalties. The dispute involved treatments for a genetic disorder. The agreement ends legal proceedings between the two companies.
How this was made
The 30-second read
Why it matters
Both firms gain certainty; BioMarin adds a new income source, Ascendis clears legal hurdles.
Market read
Settlement removes litigation risk, potentially stabilizing both stocks.
What to watch
Exact royalty rate and duration are undisclosed, affecting materiality.
Background
The settlement ends ongoing patent litigation between the two companies over treatments for a genetic disorder.
Ticker impact
BioMarin will receive royalty payments from Ascendis under a new IP settlement.
Modest upside as royalty income is added to outlook.
Royalty agreements can boost cash flow but size is unknown, limiting impact.
Ascendis Pharma agreed to pay royalties to BioMarin, ending patent disputes.
Slight downside pressure due to added cost.
Royalty obligations may affect margins; magnitude not disclosed.
Market effects
Biotech royalty settlements may signal resolution of IP disputes in rare disease space.
U.S. biotech sector may see modest confidence boost.
Limited to companies involved; no broad market effect.
Counterpoint
Royalty terms may be unfavorable, outweighing any revenue benefit.
Key entities
- CompanyBioMarin Pharmaceutical Inc.
U.S. biotech developing treatments for rare diseases.
- CompanyAscendis Pharma
U.S. biotech focused on rare disease therapeutics.
